Combining clinical trials and information technology sector expertise
Michael Stadler is a Co-Founder and President of CLARINESS, providing executive leadership and strategic direction to the company and its subsidiaries. He brings more than 20 years of experience in launching and strategic management of organizations across consumer and business-to-business industries.
Prior to co-founding CLARINESS in 2005, Michael was Managing Director for Deltavista in Germany, a provider of risk management software and services, where he developed the business plan and market entry strategy. Michael and his team successfully implemented the strategy, grew and established the company as a key presence in the risk management services industry.
Before joining Deltavista, Michael assisted in the launch of the German affiliate of one of Europe’s largest online supermarkets, and served as the Chief Financial Officer. There, he oversaw finance, human resource and purchasing functions.
Earlier roles included positions of increasing responsibility, from Business Controller to Chief Financial Officer at Tele2, an international telecommunications company. He began his career in the controlling department of Procter & Gamble, holding various financial analysis positions.
Michael earned a degree in finance & accounting from the University of St. Gallen in Switzerland.He sits on the Advisory Board of CISCRP (The Center for Information and Study on Clinical Research Participation) and is a regular speaker on several patient recruitment conferences.
Dr. Andree Beckerling joined CLARINESS in early 2019 as CEO for Clinical Solutions. In this position, Andree and his team are committed to delivering valuable patient focused solutions for pharmaceutical, medical device and biotech companies in need of patient recruitment, patient retention and patient insight services.
Over the last 20+ years Andree has served as CEO, CMO as well as in multiple other executive and operational leadership roles in the CRO industry. During this time,he gained extensive experience while managing and closely supervising numerous clinical development programs in major therapeutic areas across the globe, specifically in Europe, North America and the Asia-Pacific regions.
Andree is a trained MD, PhD, MBA and holds a degree in Pharmaceutical Medicine.
Stephanie Oelkers is the Chief Financial Officer at CLARINESS and holds the responsibility of leading the Finance department.
With her strong financial operations expertise Stephanie was inspired to start her career at CLARINESS in July 2014, and soon after established the finance department as a cross departmental business partner. Stephanie’s extensive skills and professional experiences helped her build a strong finance department.
Before joining CLARINESS Stephanie was the Deputy Chief Financial Officer of ING Lease Deutschland GmbH, initially starting as Junior Financial Controller. During Stephanie’s time there she quickly excelled and was promoted to Head of Financial Accounting & Controlling, and thereafter to Deputy Chief Financial Officer of the German entity. Prior to ING Lease Deutschland GmbH, Stephanie started her business career in the financial sector as auditing assistant for Ernst & Young.
Stephanie studied Business Law at Leuphana University of Lüneburg with a focus on taxes & auditing and graduated as Dipl. Wirtschaftsjurist.
As Chief Technology Officer, Axel Schulz leads the CLARINESS technical & development unit. Having studied computer science for media in Berlin, Axel has worked on a large variety of products in different markets like automotive, media, ecommerce and healthcare. He brings a strong technical expertise on handling large-scale architectures as well as restructuring legacy code bases preparing companies for the challenges of an ever-changing digital market.
Axel has led multiple product development and consultant teams in the past. This includes leading the project office for one of the largest publicly funded research projects in Berlin, the “Berliner Forschungsplattform Gesundheit”.
The implementation of effective team structures in combination with a healthy development culture and microservice-based architectures, are key topics for Axel approaching the development of a product.